Tmp195

The primary antibodies used were anti: MEF2D (BD Bioscience); MEF2A (C-21), (Santa Cruz Biotechnology); MEF2C (15 (link)); Actin (Sigma-Aldrich); HDAC4 (16 (link)); HDAC5 (17 (link)); HDAC7 (18 (link)); HDAC9 (19 (link)); H3K27ac (ab4729) and H3K9ac (ab4441) (Abcam); Histone H3 (H0164, Sigma-Aldrich) HDAC3 (PA5-29026, Invitrogen). The following chemicals were used: SAHA (Cayman Chemicals); TMP195 (MedChemExpress), BML-210 (Sigma-Aldrich). The PAOA derivatives MC2983, MC2984, MC2985 and MC2991 were synthetized. All new compounds had spectral (¹H NMR, ESI-MS) data in agreement with the structure. Full details of the syntheses will be reported elsewhere. NKL54 (N-(2-aminophenyl)-N'-[3-(trifluoromethyl)phenyl]heptanediamide) was synthesized by SIA Chemspace (Riga, Latvia).

The mouse was randomized before treatment so that each group had animals of similar weight and age; no blinding was done. For depletion of macrophages in vivo, Clodronate liposomes (CL, Liposoma BV) or PBS liposomes (200 μl/mouse) were injected intraperitoneally at 7, 9, and 11 dpi of the CRLM. For modulation of macrophage polarization in vivo, a class IIa Histone deacetylase (HDAC) inhibitor, TMP195 (MedChemExpress), or the solvent DMSO was injected intraperitoneally. The mice were treated with either solvent or TMP195 of 50 mg/kg daily from 7 to 12 dpi before all biopsies were collected at 14 dpi.

Bioactive low-endotoxin recombinant human vitronectin (rhVTN) was produced as described^{52 (link)}. The pan-BETi JQ1 and I-BET762 (Selleckchem or MedChemExpress), the small-molecule TLK1 inhibitor thioridazine HCl (THD; Sigma), the small-molecule CDC25 dual specificity phosphatase inhibitor NSC 663284 (MedChemExpress), and the small-molecule selective Class IIa HDAC inhibitor TMP195 (MedChemExpress) was reconstituted and stored according to the manufacturer’s instructions. The small-molecule thousand-and-one amino acids protein kinase (TAOK) inhibitor, N-[2-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl]biphenyl-4-carboxamide (referred to as compound 43)^{53 (link)}, was synthesized by SYNthesis med chem (Parkville, VIC, Australia), dissolved in DMSO, aliquoted and stored at −20°C under N₂. Bevacizumab and palivizumab were from Roche and MedImmune, respectively.